# A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial

> **NCT00622232** · PHASE2 · UNKNOWN · sponsor: **VIRxSYS Corporation** · enrollment: 40 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **GENETIC:** VRX496-transduced autologous CD4 T cells

## Key facts

- **NCT ID:** NCT00622232
- **Lead sponsor:** VIRxSYS Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-12
- **Primary completion:** 2009-01
- **Final completion:** 2023-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00622232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00622232, "A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00622232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*